Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating the Role of Janus Kinase 2 in Intestinal Homeostasis and Inflammatory Bowel Disease
EF 2020-21
Résumé
Inflammatory Bowel Disease (IBD), which groups together Crohn's disease and ulcerative colitis, will become exponentially more prevalent in Western countries. Currently, treatment aims to reduce inflammation to improve symptoms. Intestinal epithelial cells (IECs) are critical to gut health and form a protective physical and chemical barrier against gut contents. While the cause of IBD is unknown, dysfunction of this barrier is widely observed in IBD. Genetic evidence has linked variation in Janus Kinase 2 (JAK2), a protein that mediates cells' responses to various stimuli, to IBD. This suggests abnormal JAK2 may have a role in the development or progression of IBD. Our research will address the questions: what role does IEC JAK2 play in gut health and how does its status affect susceptibility to IBD and its severity? To do so, we will delete JAK2 from IECs in mice and compare their gut barrier function, levels of inflammation and tissue damage, and overall disease severity in models of IBD to normal mice. Early data shows that JAK2 deficient mice have less barrier function, higher levels of tissue damage and the pro-inflammatory molecule, IL-6, and more severe disease in a chemical model of IBD. This suggests an essential role for JAK2 in gut health. To determine if IL-6 causes the observed gut defects, IL-6 or its receptor in IECs will be genetically deleted in JAK2 deficient mice to assess whether this prevents abnormalities. Given mixed results of co-inhibiting multiple JAKs to treat IBD, differentiating between the JAKs that protect gut health and those which impact it is important and timely. Our research will clarify JAK2's role in gut health and help refine approaches to better target inflammation and protect any health-promoting, JAK-based processes in the gut.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449817
Name
Rivera Daniel C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the Role of Janus Kinase 2 in Intestinal Homeostasis and Inflammatory Bowel Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Disease; Drug Targets; Genetic Susceptibility To Disease; Inflammatory Bowel Disease; Intestinal Epithelial Cells; Intestinal Homeostasis; Molecular Biology Techniques; Pharmacology; Signal Transduction; Transgenic Animal Models Of Disease
Abstract
Inflammatory Bowel Disease (IBD), which groups together Crohn's disease and ulcerative colitis, will become exponentially more prevalent in Western countries. Currently, treatment aims to reduce inflammation to improve symptoms. Intestinal epithelial cells (IECs) are critical to gut health and form a protective physical and chemical barrier against gut contents. While the cause of IBD is unknown, dysfunction of this barrier is widely observed in IBD. Genetic evidence has linked variation in Janus Kinase 2 (JAK2), a protein that mediates cells' responses to various stimuli, to IBD. This suggests abnormal JAK2 may have a role in the development or progression of IBD. Our research will address the questions: what role does IEC JAK2 play in gut health and how does its status affect susceptibility to IBD and its severity? To do so, we will delete JAK2 from IECs in mice and compare their gut barrier function, levels of inflammation and tissue damage, and overall disease severity in models of IBD to normal mice. Early data shows that JAK2 deficient mice have less barrier function, higher levels of tissue damage and the pro-inflammatory molecule, IL-6, and more severe disease in a chemical model of IBD. This suggests an essential role for JAK2 in gut health. To determine if IL-6 causes the observed gut defects, IL-6 or its receptor in IECs will be genetically deleted in JAK2 deficient mice to assess whether this prevents abnormalities. Given mixed results of co-inhibiting multiple JAKs to treat IBD, differentiating between the JAKs that protect gut health and those which impact it is important and timely. Our research will clarify JAK2's role in gut health and help refine approaches to better target inflammation and protect any health-promoting, JAK-based processes in the gut.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rivera, Daniel C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~